|
1
|
Kohn CG, Singh P, Korytowsky B, Caranfa
JT, Miller JD, Sill BE, Marshall AC and Parikh ND: Humanistic and
economic burden of hepatocellular carcinoma: systematic literature
review. Am J Manag Care. 25:SP61–SP73. 2019.PubMed/NCBI
|
|
2
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang JD, Hainaut P, Gores GJ, Amadou A,
Plymoth A and Roberts LR: A global view of hepatocellular
carcinoma: Trends, risk, prevention and management. Nat Rev
Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim E and Viatour P: Hepatocellular
carcinoma: Old friends and new tricks. Exp Mol Med. 52:1898–907.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shek D, Chen D, Read SA and Ahlenstiel G:
Examining the gut-liver axis in liver cancer using organoid models.
Cancer Lett. 510:48–58. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Guan L, Tian H, Zeng Z, Chen J,
Huang D, Sun J, Guo J, Cui H and Li Y: Risk factors and prevention
of viral hepatitis-related hepatocellular carcinoma. Front Oncol.
11:6869622021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chavez-Tapia NC, Murúa-Beltrán Gall S,
Ordoñez-Vázquez AL, Nuño-Lambarri N, Vidal-Cevallos P and Uribe M:
Understanding the role of metabolic syndrome as a risk factor for
hepatocellular carcinoma. J Hepatocell Carcinoma. 9:583–593. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reig M, Forner A, Avila MA, Ayuso C,
Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J,
et al: Diagnosis and treatment of hepatocellular carcinoma. Update
of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI,
and SETH. Med Clin (Barc). 156:463e1–e30. 2021. View Article : Google Scholar
|
|
11
|
Mato JM, Elortza F, Lu SC, Brun V,
Paradela A and Corrales FJ: Liver cancer-associated changes to the
proteome: What deserves clinical focus? Expert Rev Proteomics.
15:749–756. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sengupta S and Parikh ND: Biomarker
development for hepatocellular carcinoma early detection: Current
and future perspectives. Hepat Oncol. 4:111–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van Thai N, Thinh NT, Ky TD, Bang MH,
Giang DT, Ha LN, Son MH, Tien DD and Lee HW: Efficacy and safety of
selective internal radiation therapy with yttrium-90 for the
treatment of unresectable hepatocellular carcinoma. BMC
Gastroenterol. 21:2162021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tzartzeva K, Obi J, Rich NE, Parikh ND,
Marrero JA, Yopp A, Waljee AK and Singal AG: Surveillance imaging
and alpha fetoprotein for early detection of hepatocellular
carcinoma in patients with cirrhosis: A Meta-analysis.
Gastroenterology. 154:1706–18e1. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beudeker BJB and Boonstra A: Circulating
biomarkers for early detection of hepatocellular carcinoma. Therap
Adv Gastroenterol. 13:17562848209317342020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marquardt JU, Galle PR and Teufel A:
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC):
An emerging field for advanced technologies. J Hepatol. 56:267–275.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pinero F, Dirchwolf M and Pessoa MG:
Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and
treatment response assessment. Cells. 9:13702020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lou J, Zhang L, Lv S, Zhang C and Jiang S:
Biomarkers for hepatocellular carcinoma. Biomark Cancer. 9:1–9.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:(Database issue).
D991–D995. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cooper LA, Demicco EG, Saltz JH, Powell
RT, Rao A and Lazar AJ: PanCancer insights from The Cancer Genome
Atlas: The pathologist's perspective. J Pathol. 244:512–524. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akram M: Mini-review on glycolysis and
cancer. J Cancer Educ. 28:454–457. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bannasch P, Ribback S, Su Q and Mayer D:
Clear cell hepatocellular carcinoma: Origin, metabolic traits and
fate of glycogenotic clear and ground glass cells. Hepatobiliary
Pancreat Dis Int. 16:570–594. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cancer Genome Atlas Research Network, .
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
GTEx Consortium, . The genotype-tissue
expression (GTEx) project. Nat Genet. 45:580–585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goldman MJ, Craft B, Hastie M, Repečka K,
McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al:
Visualizing and interpreting cancer genomics data via the Xena
platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Han D, Hou Y, Chen H and Chen Z:
Statistical inference methods for two crossing survival curves: A
comparison of methods. PLoS One. 10:e01167742015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ito K and Murphy D: Application of ggplot2
to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol.
2:e792013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The Gene
Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
American National Standards Institute and
American Type Culture Collection, . ANSI/ATCC ASN-0002-2022.
Authentication Of Human Cell Lines: Standardization Of Short Tandem
Repeat (STR) Profiling - Revised 2022. ANSI eStandards Store, by
American Type Culture Collection (ATCC). https://webstore.ansi.org/standards/atcc/ansiatccasn00022022August.
2022
|
|
33
|
Menyhart O, Nagy A and Gyorffy B:
Determining consistent prognostic biomarkers of overall survival
and vascular invasion in hepatocellular carcinoma. R Soc Open Sci.
5:1810062018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marques HP, da Silva SG, De Martin E,
Agopian VG and Martins PN: Emerging biomarkers in HCC patients:
Current status. Int J Surg. 82:70–76. 2020. View Article : Google Scholar
|
|
36
|
Shang RZ, Qu SB and Wang DS: Reprogramming
of glucose metabolism in hepatocellular carcinoma: Progress and
prospects. World J Gastroenterol. 22:9933–9943. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie H, Tong G, Zhang Y, Liang S, Tang K
and Yang Q: PGK1 drives hepatocellular carcinoma metastasis by
enhancing metabolic process. Int J Mol Sci. 18:16302017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Raddatz D and Ramadori G: Carbohydrate
metabolism and the liver: Actual aspects from physiology and
disease. Z Gastroenterol. 45:51–62. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu X, Wang H, Liang X and Roberts MS:
Hepatic metabolism in liver health and disease. Liver Pathophysiol.
391–400. 2017. View Article : Google Scholar
|
|
40
|
Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai
W and Guo C: Emerging roles and the regulation of aerobic
glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res.
39:1262020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu H, Zhu W, Qin J, Chen M, Gong L, Li L,
Liu X, Tao Y, Yin H, Zhou H, et al: Acetylation of PGK1 promotes
liver cancer cell proliferation and tumorigenesis. Hepatology.
65:515–528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang L, Wang YC, Xie XY, Chen J, Gao DM
and Ren ZG: Influence of phosphoglycerate kinase 1 on metastasis
and invasion of hepatoma cells and prognosis of liver cancer.
Zhonghua Gan Zang Bing Za Zhi. 25:446–451. 2017.(In Chinese).
PubMed/NCBI
|
|
44
|
Zhang T, Wang Y, Yu H, Zhang T, Guo L, Xu
J, Wei X, Wang N, Wu Y, Wang X and Huang L: PGK1 represses
autophagy-mediated cell death to promote the proliferation of liver
cancer cells by phosphorylating PRAS40. Cell Death Dis. 13:682022.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cao C, Zhong Q, Lu L, Huang B, Li J, Meng
L and Wei H: Long noncoding RNA MSC-AS1 promotes hepatocellular
carcinoma oncogenesis via inducing the expression of
phosphoglycerate kinase 1. Cancer Med. 9:5174–5184. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen Z, Zhuang W, Wang Z, Xiao W, Don W,
Li X and Chen X: MicroRNA-450b-3p inhibits cell growth by targeting
phosphoglycerate kinase 1 in hepatocellular carcinoma. J Cell
Biochem. 120:18805–18815. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu H, Chen H, Wu X, Sun Y, Wang Y, Zeng
Y, Chen G, Liu X, Xing X, Zhao B and Liu J: The serum proteomics
tracking of hepatocellular carcinoma early recurrence following
radical resection. Cancer Manag Res. 11:2935–2946. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pan Q, Qin F, Yuan H, He B, Yang N, Zhang
Y, Ren H and Zeng Y: Normal tissue adjacent to tumor expression
profile analysis developed and validated a prognostic model based
on Hippo-related genes in hepatocellular carcinoma. Cancer Med.
10:3139–3152. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shao F, Yang X, Wang W, Wang J, Guo W,
Feng X, Shi S, Xue Q, Gao S, Gao Y, et al: Associations of PGK1
promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation
with cancer stage and prognosis: A TCGA pan-cancer analysis. Cancer
Commun (Lond). 39:542019.PubMed/NCBI
|
|
50
|
Lim YS: Role of tumor biomarkers in the
surveillance of hepatocellular carcinoma. Korean J Gastroenterol.
78:284–288. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kern SE: Why your new cancer biomarker may
never work: Recurrent patterns and remarkable diversity in
biomarker failures. Cancer Res. 72:6097–6101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mallett S, Timmer A, Sauerbrei W and
Altman DG: Reporting of prognostic studies of tumour markers: A
review of published articles in relation to REMARK guidelines. Br J
Cancer. 102:173–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G,
Yin Z, Xie X, Wang X, Chen WZ, et al: A Large-scale, multicenter
serum metabolite biomarker identification study for the early
detection of hepatocellular carcinoma. Hepatology. 67:662–675.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pan Y, Chen H and Yu J: Biomarkers in
hepatocellular carcinoma: Current status and future perspectives.
Biomedicines. 8:5762020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fu Q and Yu Z: Phosphoglycerate kinase 1
(PGK1) in cancer: A promising target for diagnosis and therapy.
Life Sci. 256:1178632020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jiang B, Chen Y, Xia F and Li X:
PTCSC3-mediated glycolysis suppresses thyroid cancer progression
via interfering with PGK1 degradation. J Cell Mol Med.
25:8454–8463. 2021. View Article : Google Scholar : PubMed/NCBI
|
